Prognostic significance of CD8 and CD4 T cells in chronic lymphocytic leukemia

References

• Shanafelt TD, Geyer SM, Kay NE. Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL. Blood 2004;103:1202–1210.
   PubMed Web of Science ®Google Scholar
• Hallek M, Wanders L, Ostwald M, et al Serum beta(2)-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma. Leuk Lymphoma 1996;22:439–447.
   PubMed Web of Science ®Google Scholar
• Zenz T, Mertens D, Dohner H, Stilgenbauer S. Molecular diagnostics in chronic lymphocytic leukemia – pathogenetic and clinical implications. Leuk Lymphoma 2008;49:864–873.
   PubMed Web of Science ®Google Scholar
• Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999;94:1848–1854.
   PubMed Web of Science ®Google Scholar
• Crespo M, Bosch F, Villamor N, et al ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003;348:1764–1775.
   PubMed Web of Science ®Google Scholar
• Damle RN, Wasil T, Fais F, et al Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999;94:1840–1847.
   PubMed Web of Science ®Google Scholar
• Dunn, GP, Old, LJ, Schreiber, RD. The three Es of cancer immunoediting. Annu Rev Immunol 2004;22:329–360.
   PubMed Web of Science ®Google Scholar
• Clemente CG, Mihm MC Jr., Bufalino R, Zurrida S, Collini P, Cascinelli N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996;77:1303–1310.
   PubMed Web of Science ®Google Scholar
• Scanlan MJ, Simpson AJ, Old LJ. The cancer/testis genes: review, standardization, and commentary. Cancer Immun 2004;4:1.
   PubMedGoogle Scholar
• Rollins BJ. Inflammatory chemokines in cancer growth and progression. Eur J Cancer 2006;42:760–767.
   PubMed Web of Science ®Google Scholar
• Moore OS Jr., Foote FW Jr. The relatively favorable prognosis of medullary carcinoma of the breast. Cancer 1949;2:635–642.
   PubMed Web of Science ®Google Scholar
• Clark WH Jr., From L, Bernardino EA, Mihm MC. The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res 1969;29:705–727.
   PubMed Web of Science ®Google Scholar
• Pagès F, Berger A, Camus M, et al Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005;353:2654–2666.
   PubMed Web of Science ®Google Scholar
• Porrata LF, Gertz MA, Inwards DJ, et al Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin Lymphoma. Blood 2001;98:579–585.
   PubMed Web of Science ®Google Scholar
• Behl D, Porrata LF, Markovic SN, et al Absolute lymphocyte count recovery after induction chemotherapy predicts superior survival in acute myelogenous leukemia. Leukemia 2006;20:29–34.
   PubMed Web of Science ®Google Scholar
• Siddiqui M, Ristow K, Markovic SN, et al Absolute lymphocyte count predicts overall survival in follicular lymphomas Br J Haematol 2006;134:596–601.
   PubMed Web of Science ®Google Scholar
• Cox MC, Nofroni I, Ruco L, et al Low absolute lymphocyte count is a poor prognostic factor in diffuse-large-B-cell-lymphoma. Leuk Lymphoma 2008;49:1745–1751.
   PubMed Web of Science ®Google Scholar
• Porrata LF, Ristow K, Habermann TM, et al Absolute lymphocyte count at the time of first relapse predicts survival in patients with diffuse large B-cell lymphoma. Am J Hematol 2009;84:93–97.
   PubMed Web of Science ®Google Scholar
• Ege H, Gertz MA, Markovic SN, et al Prediction of survival using absolute lymphocyte count for newly diagnosed patients with multiple myeloma: a retrospective study. Br J Haematol 2008;141:792–798.
   PubMed Web of Science ®Google Scholar
• Plonquet A, Haioun C, Jais JP, et al Peripheral blood natural killer cell count is associated with clinical outcome in patients with aaIPI 2-3 diffuse large B-cell lymphoma. Ann Oncol 2007;18:1209–1215.
   PubMed Web of Science ®Google Scholar
• Palmer S, Hanson CA, Zent CS, et al Prognostic importance of T and NK-cells in a consecutive series of newly diagnosed patients with chronic lymphocytic leukemia. Br J Haematol 2008;141:607–614.
   PubMed Web of Science ®Google Scholar
• Dürig J, Nückel H, Cremer M, et al ZAP-70 expression is a prognostic factor in chronic lymphocytic leukemia. Leukemia 2003;17:2426–2434.
   PubMed Web of Science ®Google Scholar
• Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457–481.
   Web of Science ®Google Scholar
• Bisset LR, Lung TL, Kaelin M, Ludwig E, Dubs RW. Reference values for peripheral blood lymphocyte phenotypes applicable to the healthy adult population in Switzerland. Eur J Haematol 2004;72:203–212.
   PubMed Web of Science ®Google Scholar
• Herrmann F, Sieber G, Chen Z, Enders B, Komischke B, Rühl H. Further evidence for T cell abnormalities in chronic lymphocytic leukemia of the B cell type. Clin Exp Immunol 1983;53:109–114.
   PubMed Web of Science ®Google Scholar
• Kay NE, Zarling JM. Impaired natural killer activity in patients with chronic lymphocytic leukemia is associated with a deficiency of azurophilic cytoplasmic granules in putative NK cells. Blood 1984;63:305–309.
   PubMed Web of Science ®Google Scholar
• Kay NE, Zarling JA. Restoration of impaired natural killer cell activity of B-chronic lymphocytic leukemia patients by recombinant interleukin-2. Am J Hematol 1987;24:161–167.
   PubMed Web of Science ®Google Scholar
• Bartik MM, Welker D, Kay NE. Impairments in immune cell function in B cell chronic lymphocytic leukemia. Semin Oncol 1998;25:27–33.
   PubMed Web of Science ®Google Scholar
• Copson ER, Westwood NB, Majumdar G. T lymphocyte subpopulations in patients with B-cell chronic lymphocyte leukemia: relationship to infective episodes. Leuk Lymphoma 1994;14:441–446.
   PubMed Web of Science ®Google Scholar
• Kyasa MJ, Hazlett L, Parrish RS, Schichman SA, Zent CS. Veterans with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) have a markedly increased rate of second malignancy, which is the most common cause of death. Leuk Lymphoma 2004;45:507–513.
   PubMed Web of Science ®Google Scholar
• Tsimberidou AM, Wen S, McLaughlin P, et al Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma. J Clin Oncol 2009;27:904–910.
   PubMed Web of Science ®Google Scholar
• Mackus WJ, Frakking FN, Grummels A, et al Expansion of CMV-specific CD8+CD45RA+ CD27- T cells in B-cell chronic lymphocytic leukemia. Blood 2003;102:1057–1063.
   PubMed Web of Science ®Google Scholar
• Poggi A, Venturino C, Catellani S, et al Vdelta1 T lymphocytes from B-CLL patients recognize ULBP3 expressed on leukemic B cells and up-regulated by trans-retinoic acid. Cancer Res 2004;64:9172–9179.
   PubMed Web of Science ®Google Scholar
• González S, López-Soto A, Suarez-Alvarez B, López-Vázquez A, López-Larrea C. NKG2D ligands: key targets of the immune response. Trends Immunol 2008;29:397–403.
   PubMed Web of Science ®Google Scholar
• López-Larrea C, Suárez-Alvarez B, López-Soto A, López-Vázquez A, Gonzalez S. The NKG2D receptor: sensing stressed cells. Trends Mol Med 2008;14:179–189.
   PubMed Web of Science ®Google Scholar
• Foa R, Lauria F, Lusso P, et al Discrepancy between phenotypic and functional features of natural killer T-lymphocytes in B-cell chronic lymphocytic leukaemia. Br J Haematol 1984;58:509–516.
   PubMed Web of Science ®Google Scholar
• Jewell AP, Worman CP, Giles FJ, Goldstone AH, Lydyard PM. Resistance of chronic lymphocytic leukaemia cells to interferon-alpha generated lymphokine activated killer cells. Leuk Lymphoma 1992;7:473–480.
   PubMed Web of Science ®Google Scholar
• Kato N, Tanaka J, Sugita J, et al Regulation of the expression of MHC class I-related chain A, B (MICA, MICB) via chromatin remodeling and its impact on the susceptibility of leukemic cells to the cytotoxicity of NKG2D-expressing cells. Leukemia 2007;21:2103–2108.
   PubMed Web of Science ®Google Scholar
• Shanafelt TD, Geyer SM, Kay NE. Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL. Blood 2004;103:1202–1210.
   PubMed Web of Science ®Google Scholar